Periodontal DiseasesCTG + EMDNCT07233733
A Clinical Study of Connective Tissue Graft and Enamel Matrix Derivative in the Treatment of Intrabony Periodontal Defects
A study testing Connective Tissue Graft (CTG) Wall Technique, Minimally Invasive Flap Design and Root Surface Preparation and Debridement in people with Periodontal Diseases and Regeneration, run by Phạm Đình Thiên Khải at 1 site in Vietnam.
Trial summary
This clinical study aims to evaluate the effectiveness of periodontal regenerative surgery using the connective tissue graft (CTG) wall technique combined with enamel matrix derivative (EMD) in patients who have intrabony periodontal defects. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Periodontal Diseases, Regeneration
- What is being tested?
- Connective Tissue Graft (CTG) Wall Technique, Minimally Invasive Flap Design and Root Surface Preparation and Debridement
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 17 participants
- Where
- 1 siteVietnam
- Study dates
- 1 Jun 2024to 1 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults ≥18 years old who can provide written informed consent.
- Diagnosis of stage III-IV periodontitis (2017 World Workshop).
- Completed initial non-surgical periodontal therapy with good plaque control.
- Full-mouth plaque score (FMPS) ≤20% and full-mouth bleeding score (FMBS) ≤20%.
- Presence of ≥1 intrabony periodontal defect with an intrabony component ≥3 mm, confirmed clinically and radiographically.
- Probing pocket depth (PPD) at the study site ≥6 mm.
Who cannot join
- Systemic conditions or medications that could affect periodontal healing (e.g., diabetes mellitus, immunodeficiency, bisphosphonates, corticosteroids, immunosuppressants).
- Current smokers or former heavy smokers.
- Pregnancy or lactation.
- Teeth with untreated endodontic lesions or non-vital status; furcation involvement class II-III.
- Untreated occlusal trauma or tooth mobility grade II-III.
- Third molars.
Trial locations and contacts
1 site in 1 country.
Vietnam1 site
University of Medicine and Pharmacy at Ho Chi Minh City - Faculty of Odonto-Stomatology
Ho Chi Minh City, Ho Chi Minh City, 700000
About this study
Official title: Efficacy of Connective Tissue Graft Wall Technique and Enamel Matrix Derivative in the Regenerative Treatment of Intrabony Periodontal Defects: A Prospective Clinical Study
This clinical study aims to evaluate the effectiveness of periodontal regenerative surgery using the connective tissue graft (CTG) wall technique combined with enamel matrix derivative (EMD) in patients who have intrabony periodontal defects. The purpose is to determine whether this combined approach can enhance both bone regeneration and soft-tissue stability compared with the patient's initial condition.
Eligible participants will receive periodontal surgery in which a connective tissue graft and enamel matrix derivative are applied to the defect site. The study will monitor clinical improvements such as attachment gain, reduction in pocket depth, bone fill observed on cone-beam computed tomography (CBCT), and stability of the gingival margin and soft-tissue thickness. Clinical parameters (probing depth and attachment level) are recorded at baseline, 3 months, and 6 months. Gingival and hygiene parameters (recession, gingival thickness, plaque, and bleeding scores) are assessed at baseline, 1 month, 3 months, and 6 months. Radiographic bone outcomes are measured at baseline and 6 months, and early wound healing is assessed at 1 and 2 weeks.
The main goal is to assess whether CTG + EMD treatment provides predictable periodontal regeneration, improved tissue stability, and better esthetic outcomes for patients with periodontitis.
Read the detailed description
This is a prospective, single-group interventional clinical trial conducted at the University of Medicine and Pharmacy at Ho Chi Minh City to evaluate the effectiveness of the connective tissue graft (CTG) wall technique combined with enamel matrix derivative (EMD, Emdogain®, Straumann) in the regenerative treatment of intrabony periodontal defects. The study included 17 patients diagnosed with stage III-IV periodontitis who presented with radiographically confirmed intrabony defects suitable for regenerative therapy.
All participants received treatment following a standardized periodontal surgical protocol. After local anesthesia, a split-thickness vestibular releasing flap was prepared to allow coronal advancement, with external reflection of the papilla at the defect site. Thorough degranulation and root surface debridement were performed using ultrasonic and hand instruments. The root surface was conditioned with 24% EDTA gel for 2 minutes, rinsed with saline, and then enamel matrix derivative was applied onto the root surface and into the defect. A palatal connective tissue graft harvested using the four-incision technique was de-epithelialized, trimmed to span the papillae, and sutured to the buccal flap to form a stable soft-tissue wall. The flap was coronally advanced and secured with horizontal mattress and interrupted sutures to achieve tension-free primary closure.
Clinical and radiographic outcomes are evaluated at multiple time points.
Clinical parameters: probing pocket depth (PPD) and clinical attachment level (CAL) at baseline, 3 months, and 6 months.
Soft-tissue and hygiene parameters: gingival recession (buccal and interproximal), gingival thickness, full-mouth plaque score (FMPS), and full-mouth bleeding score (FMBS) at baseline, 1, 3, and 6 months.
Radiographic parameters: infrabony defect depth, buccal bone dehiscence, suprabony component, and defect angle measured on cone-beam computed tomography (CBCT) at baseline and 6 months.
Early wound healing: assessed at 1 and 2 weeks using the Early Healing Index (EHI).
The study was conducted at the Department of Periodontology, University of Medicine and Pharmacy at Ho Chi Minh City, between June 2024 and August 2025. The protocol was reviewed and approved by the Institutional Review Board of the University of Medicine and Pharmacy at Ho Chi Minh City (Approval No. 716/HĐĐĐ-ĐHYD, dated June 13, 2024). All participants provided written informed consent before enrollment.
- Conditions
- Periodontal Diseases, Regeneration
- Being tested
- Connective Tissue Graft (CTG) Wall Technique, Minimally Invasive Flap Design, Root Surface Preparation and Debridement, Growth Factor Application (EDTA + EMD), Suturing Technique
- Keywords
- connective tissue, Enamel Matrix Derivative (EMD), Periodontal Regeneration, Infrabony Defects
- Medical subject headings
- Periodontal Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Connective Tissue Graft (CTG) Wall TechniqueProcedure or surgery
Also called Connective Tissue Graft Wall Technique
After flap elevation and thorough degranulation/root debridement, a palatal connective tissue graft is harvested with the four-incision technique, de-epithelialized, and adapted to the buccal flap to create a stable soft-tissue wall.
Minimally Invasive Flap DesignProcedure or surgery
Split-thickness vestibular releasing flap with external papilla reflection to allow coronal advancement and preserve blood supply.
Root Surface Preparation and DebridementProcedure or surgery
Thorough degranulation and root surface debridement using ultrasonic and hand instruments; intraoperative recording of defect depth and morphology.
Growth Factor Application (EDTA + EMD)Biological
Conditioning of the root surface with 24% EDTA gel for 2 minutes, rinsing, followed by application of enamel matrix derivative (EMD; Emdogain®) to the root surface and into the intrabony defect.
Suturing TechniqueProcedure or surgery
Combination of horizontal mattress and interrupted sutures to achieve tension-free primary closure.
Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral TabletDrug
875/125 mg orally, twice daily for 5 days, prescribed as postoperative antibiotic therapy.
Ibuprofen (Advil)Drug
400 mg orally, three times daily for 5 days, prescribed for postoperative pain and inflammation control.
chlorhexidine mouthrinseDrug
0.12% solution, twice daily for 2 weeks, prescribed for chemical plaque control.
| Study group | Role | What they receive |
|---|---|---|
| Connective Tissue Wall + Enamel Matrix Derivative | Experimental | Periodontal regenerative surgery using a connective tissue graft (CTG) "soft-tissue wall" combined with enamel matrix derivative (EMD, Emdogain®) under a minimally invasive flap design. Receives: Procedure: Connective Tissue Graft (CTG) Wall Technique; Procedure: Minimally Invasive Flap Design; Procedure: Root Surface Preparation and Debridement; Biological: Growth Factor Application (EDTA + EMD); Procedure: Suturing Technique; Drug: Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet; Drug: Ibuprofen (Advil); Drug: chlorhexidine mouthrinse |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical Attachment Level (CAL) Gain
Change in clinical attachment level measured at the treated intrabony periodontal defect, measured with UNC-15 probe and acrylic stent. The CAL is recorded as the distance from the cementoenamel junction (CEJ) to the base of the periodontal pocket. Unit: millimeters (mm). Negative change = gain (better).
Measured: Baseline 3 months, and 6 months post-surgery
Recession Interproximal (RECi)
Distance from the cusp tip or incisal edge to the interproximal gingival margin, measured in millimeters, to evaluate changes in papillary and proximal soft tissue level after treatment. Unit: millimeters (mm). Higher = worse.
Measured: Baseline, one month, 3 months, 6 months
Radiographic Intrabony Defect Fill (mm)
Change in vertical depth of the intrabony periodontal defect measured on CBCT at the treated site. Linear distance from the alveolar crest to the base of the defect along the root surface is recorded; greater positive values indicate more defect fill. Unit: millimeters (mm). Positive fill = better.
Measured: Baseline and 6 months post-surgery
Recession Buccal (RECb)
Distance from the cusp tip or incisal edge to the buccal gingival margin (zenith point), measured in millimeters, to evaluate changes in papillary and proximal soft tissue level after treatment. Unit: millimeters (mm). Higher = worse.
Measured: Baseline, 1 month, 3 months, and 6 months post-surgery
Probing Pocket Depth (PPD)
Distance from gingival margin to base of pocket with UNC-15 probe and stent. Negative change = reduction (better).
Measured: Baseline, 3 months, and 6 months
Secondary outcomes (14)
Gingival Thickness
Buccal gingival thickness measured mid-facially using probe transparency method as described by Kan et al. (2003). Unit: categorical (thin / thick). Thick = better.
Measured: Baseline, 3 months, 6 months
Early Healing Index (EHI)
Early wound healing quality assessed according to Wachtel (2003) index. Unit: ordinal scale (1-5). 1 = best, 5 = worst.
Measured: 1 week, 2 weeks post-surgery
Full-Mouth Plaque Score (FMPS)
Percentage of tooth surfaces with visible plaque after probing, assessed according to O'Leary et al. (1972). Unit: percentage (%). Lower = better.
Measured: Baseline, 1 month, 3 months, 6 months
Full-Mouth Bleeding Score (FMBS)
Percentage of tooth surfaces with bleeding after probing, assessed according to O'Leary et al. (1972). Unit: percentage (%). Lower = better.
Measured: Baseline, 1 month, 3 months, 6 months
Defect Angle
Calculated as the angle formed between the root surface and bone crest at the defect site on CBCT images. Unit: degrees (°). Descriptive.
Measured: Baseline and 6 months.
Buccal Bone Dehiscence
Vertical distance from CEJ to the most apical part of buccal bone crest measured on CBCT to assess buccal bone resorption. Unit: millimeters (mm). Lower = better.
Measured: Baseline, 6 months.
Suprabony Component
Distance from CEJ to alveolar bone crest measured on CBCT; indicates vertical bone loss height. Unit: millimeters (mm).
Measured: Baseline, 6 months
Infrabony Defect Depth
Distance from the cemento-enamel junction (CEJ) to the base of the defect measured on CBCT; used to calculate defect depth. Unit: millimeters (mm). Descriptive
Measured: Baseline, 6 months
Sex/Gender
Male and Female
Measured: At baseline
Age
Adults, 18 years and older. Unit: years
Measured: At baseline
Defect Depth at Surgery
Distance from bonecrest to base of defect measured intraoperatively in mm
Measured: At surgery
Number of Remaining Bony Walls
Number of residual bony walls at the intrabony defect, assessed intraoperatively. This classification follows the standard defect morphology description used by Tonetti et al. (1993, 1996). A lower number of walls indicates a less favorable prognosis, while a higher number indicates better regenerative potential.
Measured: At surgery and baseline
Defect Location
Categorical (Maxilla / Mandible).
Measured: At baseline
Tooth Type
Categorical (Incisor / Canine / Premolar / Molar).
Measured: At baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2025
- Study start1 Jun 2024
- Primary completion1 Mar 2025
- Study completion1 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Periodontal DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This is a single-arm interventional clinical trial in which all enrolled patients receive periodontal regenerative surgery using the connective tissue graft wall technique combined with enamel matrix derivative (Emdogain®). The model was selected to evaluate clinical and radiographic outcomes of this specific surgical approach without a comparator group
- Masking
- None (open label)
- Enrolment
- 17 participants (actual)
Sponsor and investigators
- Lead sponsor
- Phạm Đình Thiên Khải
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Phạm Đình Thiên Khải, University of Medicine and Pharmacy at Ho Chi Minh City
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07233733
- Sponsor's protocol ID
- No. 716/HĐĐĐ-ĐHYD
- Other IDs
- 258/2025/HĐ-ĐHYD
- Acronym
- CTG + EMD
- Status last verified
- Nov 2025
- First submitted
- 26 Sep 2025
- Last updated
- 18 Nov 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Connective Tissue Graft Wall Technique and Enamel Matrix Derivative in the Regenerative Treatment of Intrabony Periodontal Defects: A Prospective Clinical Study
- ClinicalTrials.gov ID
- NCT07233733
- Acronym / sponsor ID
- CTG + EMD / No. 716/HĐĐĐ-ĐHYD
- Conditions
- Periodontal Diseases, Regeneration
- Keywords
- connective tissue, Enamel Matrix Derivative (EMD), Periodontal Regeneration, Infrabony Defects
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 17 participants (actual)
- Lead sponsor
- Phạm Đình Thiên KhảiUniversity, hospital or other
- Collaborators
- University of Medicine and Pharmacy at Ho Chi Minh City
- Study start
- 1 Jun 2024 (actual)
- Primary completion
- 1 Mar 2025 (actual)
- Study completion
- 1 Aug 2025 (actual)
- First posted
- 18 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical study aims to evaluate the effectiveness of periodontal regenerative surgery using the connective tissue graft (CTG) wall technique combined with enamel matrix derivative (EMD) in patients who have intrabony periodontal defects. The purpose is to determine whether this combined approach can enhance both bone regeneration and soft-tissue stability compared with the patient's initial condition.
Eligible participants will receive periodontal surgery in which a connective tissue graft and enamel matrix derivative are applied to the defect site. The study will monitor clinical improvements such as attachment gain, reduction in pocket depth, bone fill observed on cone-beam computed tomography (CBCT), and stability of the gingival margin and soft-tissue thickness. Clinical parameters (probing depth and attachment level) are recorded at baseline, 3 months, and 6 months. Gingival and hygiene parameters (recession, gingival thickness, plaque, and bleeding scores) are assessed at baseline, 1 month, 3 months, and 6 months. Radiographic bone outcomes are measured at baseline and 6 months, and early wound healing is assessed at 1 and 2 weeks.
The main goal is to assess whether CTG + EMD treatment provides predictable periodontal regeneration, improved tissue stability, and better esthetic outcomes for patients with periodontitis.
Detailed description
This is a prospective, single-group interventional clinical trial conducted at the University of Medicine and Pharmacy at Ho Chi Minh City to evaluate the effectiveness of the connective tissue graft (CTG) wall technique combined with enamel matrix derivative (EMD, Emdogain®, Straumann) in the regenerative treatment of intrabony periodontal defects. The study included 17 patients diagnosed with stage III-IV periodontitis who presented with radiographically confirmed intrabony defects suitable for regenerative therapy.
All participants received treatment following a standardized periodontal surgical protocol. After local anesthesia, a split-thickness vestibular releasing flap was prepared to allow coronal advancement, with external reflection of the papilla at the defect site. Thorough degranulation and root surface debridement were performed using ultrasonic and hand instruments. The root surface was conditioned with 24% EDTA gel for 2 minutes, rinsed with saline, and then enamel matrix derivative was applied onto the root surface and into the defect. A palatal connective tissue graft harvested using the four-incision technique was de-epithelialized, trimmed to span the papillae, and sutured to the buccal flap to form a stable soft-tissue wall. The flap was coronally advanced and secured with horizontal mattress and interrupted sutures to achieve tension-free primary closure.
Clinical and radiographic outcomes are evaluated at multiple time points.
Clinical parameters: probing pocket depth (PPD) and clinical attachment level (CAL) at baseline, 3 months, and 6 months.
Soft-tissue and hygiene parameters: gingival recession (buccal and interproximal), gingival thickness, full-mouth plaque score (FMPS), and full-mouth bleeding score (FMBS) at baseline, 1, 3, and 6 months.
Radiographic parameters: infrabony defect depth, buccal bone dehiscence, suprabony component, and defect angle measured on cone-beam computed tomography (CBCT) at baseline and 6 months.
Early wound healing: assessed at 1 and 2 weeks using the Early Healing Index (EHI).
The study was conducted at the Department of Periodontology, University of Medicine and Pharmacy at Ho Chi Minh City, between June 2024 and August 2025. The protocol was reviewed and approved by the Institutional Review Board of the University of Medicine and Pharmacy at Ho Chi Minh City (Approval No. 716/HĐĐĐ-ĐHYD, dated June 13, 2024). All participants provided written informed consent before enrollment.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This is a single-arm interventional clinical trial in which all enrolled patients receive periodontal regenerative surgery using the connective tissue graft wall technique combined with enamel matrix derivative (Emdogain®). The model was selected to evaluate clinical and radiographic outcomes of this specific surgical approach without a comparator group
| Arm | Type | Receives |
|---|---|---|
| Connective Tissue Wall + Enamel Matrix Derivative | Experimental | Procedure: Connective Tissue Graft (CTG) Wall Technique, Procedure: Minimally Invasive Flap Design, Procedure: Root Surface Preparation and Debridement, Biological: Growth Factor Application (EDTA + EMD), Procedure: Suturing Technique, Drug: Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet, Drug: Ibuprofen (Advil), Drug: chlorhexidine mouthrinsePeriodontal regenerative surgery using a connective tissue graft (CTG) "soft-tissue wall" combined with enamel matrix derivative (EMD, Emdogain®) under a minimally invasive flap design. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Adults ≥18 years old who can provide written informed consent.
- Diagnosis of stage III-IV periodontitis (2017 World Workshop).
- Completed initial non-surgical periodontal therapy with good plaque control.
- Full-mouth plaque score (FMPS) ≤20% and full-mouth bleeding score (FMBS) ≤20%.
- Presence of ≥1 intrabony periodontal defect with an intrabony component ≥3 mm, confirmed clinically and radiographically.
Key exclusion criteria (6 listed)
- Systemic conditions or medications that could affect periodontal healing (e.g., diabetes mellitus, immunodeficiency, bisphosphonates, corticosteroids, immunosuppressants).
- Current smokers or former heavy smokers.
- Pregnancy or lactation.
- Teeth with untreated endodontic lesions or non-vital status; furcation involvement class II-III.
- Untreated occlusal trauma or tooth mobility grade II-III.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Connective Tissue Graft (CTG) Wall TechniqueAlso: Connective Tissue Graft Wall TechniqueAfter flap elevation and thorough degranulation/root debridement, a palatal connective tissue graft is harvested with the four-incision technique, de-epithelialized, and adapted to the buccal flap to create a stable soft-tissue wall. | Procedure or surgery | Connective Tissue Wall + Enamel Matrix Derivative |
| Minimally Invasive Flap DesignSplit-thickness vestibular releasing flap with external papilla reflection to allow coronal advancement and preserve blood supply. | Procedure or surgery | Connective Tissue Wall + Enamel Matrix Derivative |
| Root Surface Preparation and DebridementThorough degranulation and root surface debridement using ultrasonic and hand instruments; intraoperative recording of defect depth and morphology. | Procedure or surgery | Connective Tissue Wall + Enamel Matrix Derivative |
| Growth Factor Application (EDTA + EMD)Conditioning of the root surface with 24% EDTA gel for 2 minutes, rinsing, followed by application of enamel matrix derivative (EMD; Emdogain®) to the root surface and into the intrabony defect. | Biological | Connective Tissue Wall + Enamel Matrix Derivative |
| Suturing TechniqueCombination of horizontal mattress and interrupted sutures to achieve tension-free primary closure. | Procedure or surgery | Connective Tissue Wall + Enamel Matrix Derivative |
| Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet875/125 mg orally, twice daily for 5 days, prescribed as postoperative antibiotic therapy. | Drug | Connective Tissue Wall + Enamel Matrix Derivative |
| Ibuprofen (Advil)400 mg orally, three times daily for 5 days, prescribed for postoperative pain and inflammation control. | Drug | Connective Tissue Wall + Enamel Matrix Derivative |
| chlorhexidine mouthrinse0.12% solution, twice daily for 2 weeks, prescribed for chemical plaque control. | Drug | Connective Tissue Wall + Enamel Matrix Derivative |
Primary outcome
Clinical Attachment Level (CAL) Gain
Time frame: Baseline 3 months, and 6 months post-surgery
Change in clinical attachment level measured at the treated intrabony periodontal defect, measured with UNC-15 probe and acrylic stent. The CAL is recorded as the distance from the cementoenamel junction (CEJ) to the base of the periodontal pocket. Unit: millimeters (mm). Negative change = gain (better).
Recession Interproximal (RECi)
Time frame: Baseline, one month, 3 months, 6 months
Distance from the cusp tip or incisal edge to the interproximal gingival margin, measured in millimeters, to evaluate changes in papillary and proximal soft tissue level after treatment. Unit: millimeters (mm). Higher = worse.
Radiographic Intrabony Defect Fill (mm)
Time frame: Baseline and 6 months post-surgery
Change in vertical depth of the intrabony periodontal defect measured on CBCT at the treated site. Linear distance from the alveolar crest to the base of the defect along the root surface is recorded; greater positive values indicate more defect fill. Unit: millimeters (mm). Positive fill = better.
Recession Buccal (RECb)
Time frame: Baseline, 1 month, 3 months, and 6 months post-surgery
Distance from the cusp tip or incisal edge to the buccal gingival margin (zenith point), measured in millimeters, to evaluate changes in papillary and proximal soft tissue level after treatment. Unit: millimeters (mm). Higher = worse.
Probing Pocket Depth (PPD)
Time frame: Baseline, 3 months, and 6 months
Distance from gingival margin to base of pocket with UNC-15 probe and stent. Negative change = reduction (better).
14 secondary outcomes
Gingival Thickness
Time frame: Baseline, 3 months, 6 months
Early Healing Index (EHI)
Time frame: 1 week, 2 weeks post-surgery
Full-Mouth Plaque Score (FMPS)
Time frame: Baseline, 1 month, 3 months, 6 months
Full-Mouth Bleeding Score (FMBS)
Time frame: Baseline, 1 month, 3 months, 6 months
Defect Angle
Time frame: Baseline and 6 months.
Buccal Bone Dehiscence
Time frame: Baseline, 6 months.
Suprabony Component
Time frame: Baseline, 6 months
Infrabony Defect Depth
Time frame: Baseline, 6 months
Sex/Gender
Time frame: At baseline
Age
Time frame: At baseline
Defect Depth at Surgery
Time frame: At surgery
Number of Remaining Bony Walls
Time frame: At surgery and baseline
Defect Location
Time frame: At baseline
Tooth Type
Time frame: At baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2025.
- Individual participant dataSharing planned: No
Related trials for Periodontal Diseases
Not yet recruitingObservational study
Periodontal Status and Biomarkers in MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Recruiting
Thermosensitive Hyaluronic Gel With Octenidine as an Adjunctive to Subgingival Instrumentation
Periodontal Disease
Active, not recruitingObservational study
A Retrospective Comparative Evaluation of Omega-3 and Resveratrol Supplementation in Patients With Periodontitis
Periodontitis
Recruiting
Effects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis
Apical Periodontitis, Endodontic Retreatment
Recruiting
Ozone Gel Versus Chlorohexidine Gel as an Adjunct to Non-Surgical Treatment of Stage II Periodontitis Grade B Among Smokers Patients
Ozone Gel, Chlorohexidine Gel
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Connective Tissue Graft (CTG) Wall Technique, Minimally Invasive Flap Design and Root Surface Preparation and Debridement in people with Periodontal Diseases and Regeneration, run by Phạm Đình Thiên Khải at 1 site in Vietnam.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Vietnam. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical Attachment Level (CAL) Gain (time frame: Baseline 3 months, and 6 months post-surgery). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2025.